INTRODUCTION
The Japan Cancer Surveillance Research Group has been involved in cancer monitoring in Japan since 2000 (1 -7) . This group aimed to estimate the cancer incidence in Japan in 2007 based on data collected from 21 out of 33 population-based cancer registries, as part of the Monitoring of Cancer Incidence in Japan (MCIJ) project. The selected registries were as follows: Iwate, Miyagi, Akita, Yamagata, Ibaraki, Tochigi, Gunma, Chiba, Kanagawa, Niigata, Toyama, Fukui, Aichi, Shiga, Kyoto, Tottori, Okayama, Hiroshima, Saga, Nagasaki and Kumamoto.
If data from all 33 registries were used, then this would have led to a large underestimation of the national cancer incidence due to incompleteness of registration in the nonselected registries. The methods of registry selection, estimation of incidence and the limitations of these methods have been previously described elsewhere (8 -10) . Briefly, we maintained the same methodology used in the MCIJ project since 2003, where we invited all 33 population-based cancer registries in Japan to participate in this study. From these registries, we selected 21 cancer registries that had highquality data, which cover 41.6% of the total population in Japan, to estimate the national incidence in 2007.
Registries that meet the following standards were considered to be a 'high-quality' data area: (i) DCO% (death certificate only: proportion of patients reported by death certificate only) of ,25%, or DCN% (death certificate notification: proportion of patients first notified via death certificate) of ,30%; and (ii) M/I (mortality to incidence ratio) of ,0.67.
In estimating cancer incidence, to remove the effects caused by the size of the registry population, an arithmetic mean of incidence rates of all eligible registries (by primary site) was used, instead of dividing the total incidence by the total population.
Cancer mortality in Japan was estimated by using the same methodology employed for the estimation of incidence, by taking mortality data from the vital statistics of the same eligible registries (1 -7). The extent of disease were evaluated by using staging criteria (i.e. cancer in situ, localized, regional lymph node metastases, direct extension to adjacent organs/tissues and distant metastasis), which were developed in Japan based on the SEER (11) to categorize properly according to the purpose in population-based cancer registry. We consider these staging criteria are suited for populationbased cancer registry, because it is vital to observe cancer incidence over time, and across primary sites. In 2007, the registries that were added as new high-quality data areas since the last estimation in 2006 were Iwate, Ibaraki, Gunma, Toyama, Shiga and Kyoto.
The incidence, crude rate, age-standardized rate and completeness and accuracy of the registries in 2007 are presented in Tables 1 (only invasive cancers) and 2 [cancers, including carcinoma in situ (CIS)]. The incidence in Japan in 2007 was estimated to be 704 090 (C00 -C96). In males, the incidence was 410 659 and in females, it was 293 431. The age-standardized incidence rate (world population) for males and females was 285.9 and 196.7, respectively (Japanese 1985 model population: the incidence rate for males was 405.3 and females was 263.8). Table 2 shows the estimated incidence of cancer including CIS. CIS was observed predominantly in females with breast and cervical cancer. In particular, the incidence of cancer including CIS was double that of cancer without CIS in the cervix.
The distribution of cancer by the extent of disease at diagnosis is presented in Table 3 . Pancreatic and lung cancers were generally more likely to be diagnosed at distant metastasis, compared with other cancers in both males and females. In the cervix, CIS accounted for a large part of the extent of disease at diagnosis (48.9%). The proportion of unknown tumor characteristics varied by the primary site. The proportion was comparatively higher for liver, gallbladder and prostate cancers, while it was lower in rectal and cervical cancers. We have to notice that these data are primarily influenced by the different methods of diagnosis and the prevalence of staging if an accurate diagnosis is not considered in some of the primary sites, for example, one primary site is more often diagnosed by tissue diagnosis than the other primary sites. In the data quality, distribution of the extent of disease might be affected by the different proportion of DCO cases which have no extent information in most cases.
The incidence according to the leading cancer types by sex is presented in Fig. 1 . Among males, in 2007, the leading cancer site was in the stomach (19.5%), followed by the lung (15.9%) and the colon and rectum (15.4%), whereas in 2006, each respective cancer site accounted for 20.4%, 15.4% and 16.0% of population (7) . Therefore, with respect to greater incidence, lung cancer was replaced by cancer in the colon and rectum in 2007. In 2007, the leading cancer 
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Cancer incidence in Japan in 2007 Per 100 000 population. b Arithmetic mean of proportion in the 21 cancer registries with high-quality data. site in females was of breasts (19.2%), followed by the colon and rectum (15.7%) and stomach (12.6%), which was similar to 2006 (7). The leading five primary sites constituted 69.7% of the total incidence in males and 62.3% in females. These proportions increase to 86.3% in males and 79.6% in females, when the leading 10 primary sites are considered.
Age-specific incidence rates for five major cancer sites for each sex are presented in Fig. 2 . Among males, the agespecific incidence trend increased with age for stomach, colon and lung cancers. In these sites, incidence rates increased in the fifth decade. For liver and prostate cancers, the incidence rate increased by the seventh decade, and remained almost flat until the highest age group. In females, trends of the age-specific incidence increased with age for stomach, colon and rectum and lung cancers. Incidence rates peaked at approximately the fourth decade for breast and cervical cancers, and at the fifth decade for corpus uteri cancer, which was clearly younger compared with the other primary sites.
The estimated cancer incidence data in Japan according to sex, cancer site, 5-year age groups and calendar year during the period of 1975 -2007 are available in a booklet format (only available in Japanese), as well as via an electronic database on the following website: http://ganjoho.jp/pro/ statistics/en/table_download.html. Additionally, the results from the trend analyses of cancer incidence and mortality in Japan are presented in another article in this issue (12) . 
334
Cancer incidence in Japan in 2007
